Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Allogene Therapeutics Announces Participation in December Investor Conferences GlobeNewswire - Tue Nov 19, 7:30AM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Announces Promising Preclinical Data for ALLO-329, an AlloCAR T™ Therapy Targeting Autoimmune Diseases Quiver Quantitative, Inc. - Mon Nov 18, 5:52PM CST

ALLO-329 shows promise in treating autoimmune diseases by targeting CD19+ B cells and CD70+ T cells without lymphodepletion.Quiver AI SummaryAllogene Therapeutics has announced promising preclinical data...

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence GlobeNewswire - Mon Nov 18, 7:30AM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics: Q3 Earnings Snapshot AP - Thu Nov 7, 3:11PM CST

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update GlobeNewswire - Thu Nov 7, 3:02PM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS GlobeNewswire - Thu Nov 7, 9:00AM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for... GlobeNewswire - Tue Nov 5, 8:10AM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Announces Participation in November Investor Conferences GlobeNewswire - Mon Nov 4, 7:30AM CST

ALLO : 2.05 (-3.30%)
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update GlobeNewswire - Wed Oct 30, 7:30AM CDT

ALLO : 2.05 (-3.30%)
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) GlobeNewswire - Tue Oct 29, 7:30AM CDT

ALLO : 2.05 (-3.30%)

Barchart Exclusives

Using Option To Generate Extra Income From Your Bond Investments Barchart - 19 minutes ago
With markets looking increasingly volatile, investors might be more interested in generating income rather than capital gains. Bond investments have seen significant capital losses in recent months as inflation concerns continue to have investors anxious. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot